These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 36334454)
1. Synthesis and antineoplastic activity of ethylene glycol phenyl aminoethyl ether derivatives as FOXM1 inhibitors. Gao Y; Geng J; Xie Z; Zhou Z; Yang H; Yi H; Han X; Xue S; Li Z Eur J Med Chem; 2022 Dec; 244():114877. PubMed ID: 36334454 [TBL] [Abstract][Full Text] [Related]
2. Structure-based virtual screening towards the discovery of novel FOXM1 inhibitors. Xie ZS; Zhou ZY; Sun LQ; Yi H; Xue ST; Li ZR Future Med Chem; 2022 Feb; 14(4):207-219. PubMed ID: 34809496 [No Abstract] [Full Text] [Related]
3. A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells. Abusharkh KAN; Comert Onder F; Çınar V; Hamurcu Z; Ozpolat B; Ay M Med Oncol; 2024 Jun; 41(8):188. PubMed ID: 38918225 [TBL] [Abstract][Full Text] [Related]
4. Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells. Chan-On W; Huyen NT; Songtawee N; Suwanjang W; Prachayasittikul S; Prachayasittikul V Drug Des Devel Ther; 2015; 9():2033-47. PubMed ID: 25897210 [TBL] [Abstract][Full Text] [Related]
5. SP1-independent inhibition of FOXM1 by modified thiazolidinediones. Tabatabaei Dakhili SA; Pérez DJ; Gopal K; Haque M; Ussher JR; Kashfi K; Velázquez-Martínez CA Eur J Med Chem; 2021 Jan; 209():112902. PubMed ID: 33069434 [TBL] [Abstract][Full Text] [Related]
6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
7. The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3. Zhang Z; Bu H; Yu J; Chen Y; Pei C; Yu L; Huang X; Tan G; Tan Y Theranostics; 2019; 9(10):2882-2896. PubMed ID: 31244930 [TBL] [Abstract][Full Text] [Related]
8. In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer. Chen Y; Ruben EA; Rajadas J; Teng NNH Bioorg Med Chem; 2015 Aug; 23(15):4576-4582. PubMed ID: 26164623 [TBL] [Abstract][Full Text] [Related]
9. Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers. Khade AB; Kar SS; Alummoottil CT; Tiwari A; Tiwari M; Eshwara VK; Bhat P; Giliyar VB; Shenoy GG Med Chem; 2020; 16(2):256-270. PubMed ID: 30848207 [TBL] [Abstract][Full Text] [Related]
10. FOXM1 Inhibitors as Potential Diagnostic Agents: First Generation of a PET Probe Targeting FOXM1 To Detect Triple-Negative Breast Cancer in vitro and in vivo. Pérez DJ; Amirhossein Tabatabaei Dakhili S; Bergman C; Dufour J; Wuest M; Juengling FD; Wuest F; Velázquez-Martínez CA ChemMedChem; 2021 Dec; 16(24):3720-3729. PubMed ID: 34402202 [TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells. Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278 [TBL] [Abstract][Full Text] [Related]
13. A new target for proteasome inhibitors: FoxM1. Gartel AL Expert Opin Investig Drugs; 2010 Feb; 19(2):235-42. PubMed ID: 20074015 [TBL] [Abstract][Full Text] [Related]
14. Apoptosis induced by 7-difluoromethoxyl-5,4'-di-n-octyl genistein via the inactivation of FoxM1 in ovarian cancer cells. Ning Y; Li Q; Xiang H; Liu F; Cao J Oncol Rep; 2012 Jun; 27(6):1857-64. PubMed ID: 22447287 [TBL] [Abstract][Full Text] [Related]
15. Targeting FOXM1 in cancer. Halasi M; Gartel AL Biochem Pharmacol; 2013 Mar; 85(5):644-652. PubMed ID: 23103567 [TBL] [Abstract][Full Text] [Related]
16. A structure-activity relationship study of Forkhead Domain Inhibitors (FDI): The importance of halogen binding interactions. Tabatabaei Dakhili SA; Pérez DJ; Gopal K; Tabatabaei Dakhili SY; Ussher JR; Velázquez-Martínez CA Bioorg Chem; 2019 Dec; 93():103269. PubMed ID: 31654840 [TBL] [Abstract][Full Text] [Related]
17. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Wierstra I Adv Cancer Res; 2013; 119():191-419. PubMed ID: 23870513 [TBL] [Abstract][Full Text] [Related]
18. A novel peptide, 9R-P201, strongly inhibits the viability, proliferation and migration of liver cancer HepG2 cells and induces apoptosis by down-regulation of FoxM1 expression. Bi Z; Liu W; Ding R; Wu Y; Dou R; Zhang W; Yuan X; Liu X; Xiong L; Guo Z; Mao C Eur J Pharmacol; 2017 Feb; 796():175-189. PubMed ID: 28012972 [TBL] [Abstract][Full Text] [Related]